Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.59 |
| ▸ | EHMT2 | Q96KQ7 | 19/20 | 0.59 |
| ▸ | RCOR1 | Q9UKL0 | 18/20 | 0.58 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.53 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427783 | 0.93 | EHMT2 (0.60) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL9911778 | 0.92 | EHMT2 (0.59) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL4205091 | 0.92 | EHMT2 (0.61) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL1427800 | 0.92 | EHMT2 (0.59) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL1428116 | 0.92 | EHMT2 (0.71) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL1427703 | 0.91 | EHMT2 (0.65) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL1427730 | 0.91 | EHMT2 (0.65) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL9911777 | 0.91 | EHMT2 (0.67) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL1427871 | 0.91 | EHMT2 (0.56) | KDM1AEHMT2RCOR1EZH2PRMT1 | |
| SCHEMBL1427822 | 0.90 | EHMT2 (0.68) | KDM1AEHMT2RCOR1EZH2PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-102105463-A | Bicyclic compounds active on the CXCR4 receptor | ALLERGAN INC | 2011-06-22 | — | — | CN | disclosed |
| EP-2300456-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | CXCR4, CXCR2, CXCL12 | KDM1A 4804/4885EHMT2 4669/4885RCOR1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.